Exchange: NASDAQ·Updated 07:55 PM EST
ANNX logo

ANNX Annexon Inc

$3.10
$0.31
(9.09%)
Today
Closed $3.10
$0.31
(10.00%)
After Hours
Reported EarningsNov 9
Mkt Cap$591.37M
Vol4.46M

About ANNX

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
59

Bullish Sentiment

How do you feel about ANNX?

Biotech80
🚀 $ANNX BIG CATALYSTS AHEAD! Annexon could be approaching a transformational period. 🔥 ARCHER II: Month-15 DMC assessment approaching. Positive efficacy and safety signals could be a major turning point for vonaprument. 🔥 TANRUPRUBART: European regulatory review underway, with US BLA submission targeted for Q4 2026. Huge potential in Guillain-Barré syndrome. 🔥 ANX1502: Another potential value driver with proof-of-concept data ahead. 💰 $209.2M cash and investments at June 2026, plus credit-facility access and management guidance for runway into 2028. 📊 31.6M shares reported short as of October 15. Next short-interest update November 10. Multiple clinical programmes. Multiple catalysts. Significant potential. If the data deliver, the market could be forced to reassess Annexon’s value. The next few months could be pivotal. Don’t lose sight of what is building here! 🚀 $ANNX
7
Aawilliam2003
$ANNX I’ve been thinking about and spending a lot of time researching this stock over the past 6 months. Talked to a lot of people. Quite obvious massive upside potential, but lots of doubters too. Decided to add this past week - let’s see what happens
6
dcrown
$ANNX let’s be clear A ≥15-letter loss represents dropping three full lines on the standard ETDRS eye chart at two consecutive clinical visits. This is a functional vision preservation metric rather than a purely structural measurement of lesion growth When a treatment prevents this from happening, it means the treatment successfully preserved real-world, usable vision for the patient, which matters much more to daily life than just slowing down a spot on a scan.
6
Biotech80
$ANNX 🚀 THE NEXT 12 MONTHS COULD BE TRANSFORMATIONAL! Annexon’s Q3 update brings serious momentum: 🔥 ARCHER II Month-15 assessment on track for Q4. 90% patient retention. Two US sub-study assessments potentially following in Q1 2027. 🔥 TANRUPRUBART: 18 patients treated in FORWARD. European MAA under review and US BLA submission expected this quarter. 🔥 ANX1502: Proof-of-concept completed, with encouraging biomarker reductions and no significant safety signals. 💰 $213.4M cash and investments. Expected runway into 2028, backed by a $200M credit facility. Three clinical programmes. Two registrational programmes. Multiple major catalysts ahead. The next 12 months could fundamentally change how the market values Annexon. The clinical data will decide the story. But the opportunity ahead deserves serious attention. Watch $ANNX! 🚀
4
betonthenews
$ANNX ARCHER IIPhase 3 Trial in Dry AMD With GA vs KOD's Phase 3 DAYBREAK study of both tarcocimab and KSI-501 in patients with treatment naive neovascular age-related macular degeneration (wet AMD): 659 vs 675 patients enrolled DAYBREAK Topline timeline: Last patient visit in Aug 2026 "Completed enrollment in the Phase 3 DAYBREAK study of both tarcocimab and KSI-501 in patients with treatment naive neovascular age-related macular degeneration (wet AMD) DAYBREAK enrolled approximately 690 subjects, with last visit for the 48-week primary endpoint expected in August 2026." Topline data: September 28, 2026 at 6:30 AM EDT Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD July 24, 2025 at 7:00 AM EDT Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument Last patient visit: OCT 2026... If ANNX follows DAYBREAK topline time range: Late Nov to early Dec.
1
1
Biotech80
$ANNX 🚀 A MAJOR CATALYST WINDOW IS NOW OPEN! Annexon’s ARCHER II Month-15 DMC assessment is expected Q4 2026 potentially the most important near-term event for the company. 🔥 Does the DMC determine that the primary endpoint has been met? 🔥 If successful, will it trigger assessment of the two pre-specified US sub-studies, with results expected in Q1 2027? 🔥 If not, the trial continues towards Month-24 results, expected Q3 27. * 659 patients enrolled. * 90% patient retention. * $213.4M cash and investments. * Management expects funding into 2028. Meanwhile, tanruprubart’s European MAA is under review, although US FDA feedback has raised additional-data concerns. The key date to watch is the ARCHER II DMC announcement expected before the end of December 2026. A positive assessment could materially strengthen the case for vonaprument and change how the market values Annexon’s pipeline. No guaranteed outcome this is a clearly defined, potentially thesis-changing catalyst. 🚀 $ANNX
3
Determinedstocks
$ANNX This was a great call. Confident management. Confident on the data. Management had answers for all the analyst questions. Its either a great dog and pony show from a bunch of lying crooks - could be - or the Annexon team is convinced that they have a blockbuster in the making.
3
makingdoughfromoptions
$ANNX Their two drugs, GBS and GA are the FIRST to effectively treat either condition. GBS is undisputed and GA should, note, should prove out well too. I am looking for 10X current SP in 5-6 years. Sales and probable income support it with excellent uptake. Don't be surprised if they get acquired after approvals here and EU. Do not trade....hang on for the ride.
3
djmojo1485
$ANNX I am not that confused as the below seems pretty straightforward (From August): With a dual primary endpoint strategy, ARCHER II can achieve success in protecting against vision loss at either Month 15 or 24, which are independent efficacy timepoints. “Our objective is to maximize the best-in-class potential of vonaprument to preserve visual acuity for millions of patients at risk of irreversible vision loss. The strong power and execution of our Phase 3 ARCHER II trial provide a clear opportunity to seamlessly incorporate a Month 24 dual primary endpoint while maintaining the Month 15 primary endpoint.... “As ARCHER II was already designed to remain masked through Month 24, this strategic addition allows us to also evaluate the longer-term profile of vonaprument for inclusion into the label without change to the study operation. We look forward to delivering the Month 15 data milestone on schedule in the fourth quarter of this year and delivering Month 24 data thereafter.....
3
Carnagex
$ANNX Phase 2 was more successful then people gave it credit for. In my opinion vision loss is clinically the more important endpoint. Phase 2 was highly significant and vision loss was 4x less in the monthly treatment group. It wasn’t a small trial either or tiny number of patients. They need to just repeat the results in phase 3 and there is room for shrinkage if the effect. Even as much as 40-50% reduction could still be statistically significant. Looking forward to the results and so are my shares.
2
Itsybitsybeanbag
$ANNX “Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. “
2
dcrown
$ANNX 60% of all open interest in ANNX, pricing in a massive binary move into early 2027
1
betonthenews
$ANNX The interesting thing is that 109.87% of Shares Held by Institutions for such a small cap biotech company, maybe they believe in something???
1
Lightening_strikes
$ANNX holding this stock is just brutal Management is clearly not believed And they are towing their time
1
Thomas105
$ANNX Instead of competing against each other, both drugs are competing against different established treatments within their respective markets. Zenkuda is competing against established wet AMD blockbusters like Eylea HD and Vabysmo. Meanwhile, Vonaprument is trying to establish itself as a unique vision-preserving alternative in the dry AMD/GA space.
1
RandomInvestor777
$ANNX majority of alpha allocated to month 15. good sign, but this means even more if month 15 doesn't hit it's over
1
Lightening_strikes
$ANNX 1 month or so from major mews and we can’t hold $4 This is a FAILURE of the team to convince buyers
1
RandomInvestor777
$ANNX I feel it was pretty clear? the Q4 news will be whether the trial progresses to 24 mo (and stays blinded) or stops (for success / failure). If its sucess then the substudy analysis will be in Q1 2027. the stock reaction will depend on the DMC decision in Nov/Dec
1
Itsybitsybeanbag
$ANNX Great dishing out more options! These guys have blown through 200 mil for an 80 mil trial in the last year and a half. Criminals enriching themselves to our detriment
1
djmojo1485
$ANNX maybe they can keep putting out these decks for another few days and get the stock price back to 6/7 a share
1

Advertisement|Remove ads.